US FDA approves Amylin's diabetes drug

WASHINGTON (Reuters) - Amylin Pharmaceuticals won U.S. approval on Friday for its Bydureon diabetes drug, a long-awaited victory for the company's most promising product. After two delays, the Food and Drug Administration approved once-weekly ...